Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation

Sitharthan Kamalakaran1, Jude Kendall2, Xiaoyue Zhao2, Chunlao Tang2, Sohail Khan2, Kandasamy Ravi2, Theresa Auletta2, Michael Riggs2, Yun Wang3, Åslaug Helland3,4, Bjørn Naume4, Nevenka Dimitrova1, Anne-Lise Børresen-Dale3,5, Jim Hicks2 and Robert Lucito2,*

1Philips Research North America, Briarcliff Manor, NY 10510, USA, 2Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, 3Department of Genetics, Institute for Cancer Research, 4Department of Oncology, Norwegian Radium Hospital, Rikshospitalet University Hospital and 5Faculty Division, The Norwegian Radium Hospital Faculty of Medicine, University of Oslo, Oslo, Norway

Received October 9, 2008; Revised April 29, 2009; Accepted May 2, 2009

ABSTRACT
Methylation of CpG islands associated with genes can affect the expression of the proximal gene, and methylation of non-associated CpG islands correlates to genomic instability. This epigenetic modification has been shown to be important in many pathologies, from development and disease to cancer. We report the development of a novel high-resolution microarray that detects the methylation status of over 25,000 CpG islands in the human genome. Experiments were performed to demonstrate low system noise in the methodology and that the array probes have a high signal to noise ratio. Methylation measurements between different cell lines were validated demonstrating the accuracy of measurement. We then identified alterations in CpG islands, both those associated with gene promoters, as well as non-promoter-associated islands in a set of breast and ovarian tumors. We demonstrate that this methodology accurately identifies methylation profiles in cancer and in principle it can differentiate any CpG methylation alterations and can be adapted to analyze other species.

INTRODUCTION
It has become increasingly clear how epigenetic modification can affect the structure and the expression of genes encoded in the DNA. One such modification is the methylation of cytosines that are 5' to guanines, so-called CpG dinucleotides. Found scattered across the genome, although at a lower than expected frequency, CpG dinucleotides also cluster into what have been termed CpG islands. The definition of a CpG islands differs somewhat based on the algorithm used for identification, two commonly used algorithms being Gardiner-Garden and Frommer (1) and Takai-Jones (2). The islands identified can be classified as falling into two distinct classes, those that are overlapping or proximal (within 2000 bp) to the transcription start site (TSS) of genes and those that are not associated with any transcription start site (non-TSS) for an obvious gene. Most CpG islands proximal to the TSS of genes (TSS–CGIs) are largely unmethylated normally, and methylation of these islands, as can occur during tumorigenesis, has been shown to correlate highly to the suppression of transcription (3). Of the non-TSS CpG islands (non-TSS–CGIs) in the genome, many of these are proximal or inclusive to repetitive sequences, and are generally heavily methylated in normal tissue (4,5). However, during tumorigenesis hypomethylation occurs at these islands (4,5), which can result in the expression of certain repeats (6,7). Interestingly, this hypomethylation correlates to the severity of some cancers (8,9) and DNA breakage and genome instability (10).

Under certain circumstances, which can occur in pathologies such as cancer, imprinting, development, tissue specificity and X-chromosome inactivation, TSS–CGIs can be heavily methylated (11). Specifically, in cancer, methylation of islands proximal to tumor suppressor genes such as p16, RASSF1A, BRCA1, is a frequent event (12–14). Since the analysis of such genes was previously done one at a time using bisulfite sequencing, the value of accurate high-throughput methods is obvious.

Several higher throughput methods, many array based, have been developed to identify CpG methylation in the...
METHODS

Materials

Enzymes, MspI,McRBC, T4 DNA ligase, were supplied by new England Biolabs. Primers were supplied by Sigma Genosys. Cot1 DNA and tRNA were supplied by invitrogen.

METHODS

Samples

Cell lines, SKBR3, Huh7, PANC1, were acquired through ATCC and grown according to specified conditions. The cell line chp-skn-1 is a primary fibroblast cell line cultured from a skin sample provided by an anonymous donor, cultured under the following conditions: DMEM + 20% FBS, Penn/Strep, and non-essential amino acids. Tumor DNA from 11 patients with advanced ovarian carcinomas who were treated at the Department of Gynecological Oncology at the Norwegian Radium Hospital (NRH) during the period May 1992 to February 2003 were included in this study. The collection is approved by the Regional ethical review board (Reference No: S-01127). Tumor DNA from 28 patients treated for localized breast cancer at The Norwegian Radium Hospital (NRH) from 1995 to 1998 was included in this project. The samples were collected under an informed consent and the project approved by the local REK/IRB (30). A small number of samples 12 breast tumors and 12 normals and 7 ovarian normals were obtained from The Cooperative Human Tissue Network, a repository of tumor material run by the National Institutes of Health.

Methylation array and detection

Coverage. Our approach to map genome-wide methylation involves tiling all the predicted CpG islands. All annotated CpG islands were obtained from the UCSC genome browser. These islands were predicted using the published Gardiner-Garden and Frommer (1) definition and involves the following criteria: length ≥200 bp, %GC ≥50%, observed/expected CpG ≥0.6. There are ~26,219 CpG islands in the range of 200–2000 bp in the genome. These islands are well covered by MspI restriction fragmentation. Arrays were manufactured by NimbleGen Systems Inc. using the 390K format to the following specifications. The CpG island annotation from human genome build 33 (hg17) was used to design a 50-mer tiling array. The 50mers were shifted on either side of the island sequence coordinates to evenly distribute the island. The 390K format has 3,676,580 available features which would not fit all islands with a 50-mer tiling. Therefore, we made a cutoff on the islands to be represented based on size, with only CpG islands of size 200–2000 bp being assayed. The array represents classical CpG islands and does not include imprint control regions or other non-island promoters known to be methylated. Background hybridization signal could be high with probes of high GC content since by definition these probes will be. Therefore, control probes, which are not in an MspI representation, were designed to represent background signal, and these probes were used to calculate signal to noise (see Supplementary Figure 2). Array design, probe sequences and further annotation are available on line http://www.ncbi.nlm.nih.gov/geo/, data-set number GSE15801.

Sample preparation and hybridization

Representations have been described previously (29), with the following changes. The primary restriction endonuclease used is MspI. After the digestion the following linkers were ligated (MspI24mer CAGCATGAGACTGA ACGCAGCA, and MspI12mer CGCTGCTGCGTT. The 12 mer is not phosphorylated and does not ligate. After ligation the material is cleaned by phenol chloroform, precipitated, centrifuged and resuspended. The material is divided in two, half being digested by the endonuclease McrBC and the other half being mock digested according to specification by New England Biolabs.
The digestion time is 3 h. As few as four 250 μl tubes were used for each sample pair for amplification of the representation each with a 100 μl volume reaction. The cycle conditions were 95°C for 1 min, 72°C for 3 min, for 15 cycles, followed by a 10-min extension at 72°C. The contents of the tubes for each pair were pooled when completed. Representations were cleaned by phenol:chloroform extraction, precipitated, resuspended and the concentration determined. Representations were run on a gel to check for content, the McrBC digested representation being ~100–150 bp shorter on average than the Mock. DNA was labeled as described with minor changes (29). Briefly, 2 μg of DNA template was placed (dissolved in TE at pH 8) in a 0.2 ml PCR tube. Five microliters of random nonomers (Sigma Genosys) were added brought up to 25 μl with dH2O, and mixed. The tubes were placed in Tetrad at 100°C for 5 min, then on ice for 5 min. To this 5 μl of NEB Buffer 2, 5 μl of dNTPs (0.6-nm dCTP, 1.2-nm dATP, dTTP, dGTP), 5 μl of label (Cy3-dCTP or Cy5-dCTP) from GE Healthcare, 2 μl of NEB Klenow fragment and 2 μl dH2O were added. Procedures for hybridization and washing were followed as reported previously (29) with the exception that oven temperature for hybridization was increased to 50°C. In general two hybridizations were performed for all samples (carried out as dye swaps to decrease variation of labeled nucleotide incorporation) with the exception for samples analyzed in Figure 2 where four hybridizations were performed.

Data analysis and statistics

Microarray images were scanned on GenePix 4000B scanner and data extracted using NimbleScan software (Nimblegen Systems Inc.). For each probe, the geometric mean of the ratios (GeoMeanRatio) of McrBc and control treated samples were then calculated for each experiment and its associated dye swap. The GeoMeanRatios of all the samples in a dataset were then normalized using quantile normalization method (31). The normalized ratios for each experiment were then collapsed to get one value for all probes in every MspI fragment using the median polish model. The collapsed data were then used for further analysis (32). Collapsed fragment data were then subjected to Welch’s two-sample t-test for identifying significant differences between tumors and normals. P-values were corrected for multiple testing by controlling false discovery rate (FDR) (Benjamini-Hochberg algorithm) (33) implemented in R [multitest package (34)]. Significance threshold was set at 0.001 for breast and 0.05 for the smaller ovarian set.

General computations and statistics were performed in Python (35), S-Plus and R (32).

Bisulfite sequencing

Probes were identified with differing methylation between the two samples, SKBR3 and chp-skn-1. DNAs from the two samples were treated with bisulfite using the EZ DNA Methylation-Gold Kit (Zymo Research, CA, USA). PCR primers were designed to flank the corresponding MspI fragments using MethPrimer (36). For two fragments, the PCR-amplified fragments were ligated and transformed using the TOPO-TA Cloning kit (Invitrogen, CA, USA); the transformant clones were picked for plasmid extraction, which were then sequenced. To increase throughput, the remaining 32 were sequenced as PCR products. Results for subcloning and direct sequencing were compared to determine the peak heights required to call heterozygotes.

McrBC PCR

The sequence of the MTSS1 CpG island was obtained, including sequence beyond the ends of the island to aid in the design of PCR primers. Genomic DNA was digested with McrBC or mock digested followed by heat killing. Ten nanograms of DNA was used for PCR with Qiagen Taq polymerase for 30 cycles. Ten microliters of this product was then used as template for an additional 15 cycles of PCR. Products were run on 2% agarose gel, and pictures were taken to illustrate the fragments that were methylated.

RESULTS

In order to further investigate the role that CpG island methylation plays in cancer, we have designed a new comprehensive CpG island microarray and have developed robust methods for its use. While sharing some similarities to previously developed methylation arrays (22,27,37), our method has several features that allow for increased CpG-island coverage and sensitivity. First, we utilized high-density oligonucleotide arrays with close to 400K features that allowed us to maximize tiling coverage of 26 219 out of 27 801 (HG17) annotated CpG islands (which includes non-promoter islands), while other CpG island arrays only contain selected promoter sequences (22,37). Second, our hybridization target, because it is made from MspI representations, enriches for CpG island sequences by 10-fold relative to total genomic DNA (based on the size or the MspI amplifiable fragment) and thus provides superior hybridization specificity. In addition since this method is representational based, very little DNA is required (as little as 50 ng) which makes this method well suited to the analysis of primary tumors. Third, each island generally corresponds to multiple MspI fragments, yielding positional information of which portion of an island is methylated. Finally, our method is based on enzymatic depletion of methylated sequences with fewer steps than other methods (37,38); having fewer steps may be less prone to variability. The enzyme chosen for depletion, McrBC, has the unusual recognition site A/GCm(N_40–3000)A/GCm and has been used by others to analyze methylation including its application to arrays (39,40). This enzyme recognizes two methyl groups and because of the varied distance and that the methyl groups can be on the same or both strands (41), a type of combinatorial recognition and cleavage occurs, which greatly increases the number of potentially methylated CpG dinucleotides that can be queried. Using in-silico analysis we calculate using McrBC (specifically the preferred distance for recognition between methyl cytosines of 40–150 bp) our methodology queries over
were grown and DNA prepared. Representations were
fibroblast cell line (chp-skn-1). Two cultures of chp-skn-1
noise in the system we performed analysis on a normal
initial experiments with cell lines. To determine the level of
the methylation state of CpG islands, we first performed
designed oligonucleotide array.

The procedure as schematized in Figure 1 involves
digesting the genome with a restriction endonuclease MspI and adaptors ligated. The
ligated material is divided evenly, one half being digested with
McrBC and the other half being mock digested. This material is used
as template for PCR amplification and the resulting product is used
for microarray comparison.

Figure 1. Schematic of the procedure. Shown at the top is genomic
DNA with a CpG island that is methylated. The DNA is cleaved
with the restriction endonuclease MspI and adaptors ligated. The
ligated material is divided evenly, one half being digested with
McrBC and the other half being mock digested. This material is used
as template for PCR amplification and the resulting product is used
for microarray comparison.

1 million of the 1.7 million CpG dinucleotides occurring in
CpG islands, much more than can be queried by other
techniques that utilize different enzymatic depletions
such as HpaII and MspI (~225 000). This gives our meth-
odology a 4-fold increase in potential coverage over other
methods. According to these calculations combined with
the increased array coverage (where we include non-pro-
moter sequences and do not discriminate against any other
promoter sequences except for larger islands, see ‘Methods
for array design’ section) we will have increased the level
of DNA methylation that can be measured in the genome
over other methods which either use restriction enzymes
or limited array coverage (data not shown).

The procedure as schematized in Figure 1 involves
digesting the genome with a restriction endonuclease with a CG-rich recognition sequence (MspI), and ligation
of adaptors for use in a subsequent step of reducing geno-
mic complexity. We next divide the ligation in half and
deplete one-half of its methylated sequences by digestion
with the methylation-specific endonuclease, McrBC (37),
and mock treat the other half. In both cases, we use care-
fully balanced PCR conditions to size select MspI frag-
ments and reduce the overall genome complexity as previously described (29). The McrBC-treated representa-
tion is compared to the mock-treated sample that serves as
the reference for comparative hybridization to the
designed oligonucleotide array.

To determine if our method accurately identifies the
methylation state of CpG islands, we first performed
initial experiments with cell lines. To determine the level of
noise in the system we performed analysis on a normal
fibroblast cell line (chp-skn-1). Two cultures of chp-skn-1
were grown and DNA prepared. Representations were
prepared and were used to compare hybridization results
from the same representations, representation from the
same sample prepared separately, as well as the chp-skn-
1 grown separately. Generally two hybridizations are per-
formed one being a dye swap to decrease variation but in
this case four hybridizations were performed for all condi-
tions; however to demonstrate how little noise there is in the system, results and correlation from a single
hybridization were compared graphically shown in
Figure 2A–C. The close correlation demonstrates the
small variation in the representational process, the labeling
and the hybridization. We also found little variation
among different lots of McrBC (data not shown).

Finally, we compared the results of our methodology on
the two cell lines HPDE and PANCl with results from the
same two cell lines reported by Sato and colleagues using a
different method and different array design (44). Although
there were some differences in detection between the two
methods they were in good agreement (68%) for islands
methylated in the samples. Of the 34 interesting islands
listed and validated, 26 were represented on our array
Figure 2. Comparison of methylation analysis of cell lines. (A–C) shows the comparison of a normal fibroblast used to produce representations from two separate aliquots of DNA and the representations were analyzed and the intensity compared to each other by scatter plot; the intensities of each being on one and the other axis, and the correlation calculated: (A) being replicate hybs, (B) being technical replicates and (C) being biological replicates. (D) The comparison of the breast cancer cell line SKBR3 and the normal female fibroblast cell line as a scatter plot of the intensities from the SKBR3 experiment as the y-axis and the intensities of chp-skn-1 on the x-axis, and the correlation shown. (E) An example of bisulfite validation for a fragment found methylated in the tumor and not in the normal at a CpG island at chr 9:2197965–21980065, which lies upstream of the p14 gene. The original data showing the ratio differences is shown with the position of the fragment. To the right is the electropherogram identifying a region of cytosines that do not convert and at the bottom is a short table identifying the genomic position and number of McrBC site. (F) shows data for the cell line Huh7 compared to the normal cell line chp-skn-1 for the p16 gene CpG island graphed by genomic position. The x-axis is the genomic position of the probes and the y-axis is the ratio of two experiments, blue being chp-skn-1 and orange being Huh7. Inset above is shown is the relation of the transcript and inset below is the relation of the CpG island to the probes.
obtained with unmatched samples as a set and measured our results obtained with matched samples to those tumor-normal pairs could be analyzed first we compared unmatched tumor samples. To determine if unmatched pairs. As with many tumor banks, ours contain many and we have done this for 12 breast tumor and normal profiling is to utilize matched normal-tumor samples, used by SATO and colleagues.

It is apparent that the tumors are on the whole distinct from the normals in comparison with each other (P < 10E–017).

The mean correlation for each sample with the normal samples (mean of 12 correlations for each tumor and 11 correlations for each normal) is shown. The 12 samples to the left of the vertical line are the normals. The 40 to the right are tumors. The horizontal line is drawn at the minimum mean correlation for the normals with normals. It is apparent that the tumors are on the whole distinct from the normals in comparison with each other (P < 10E–017).

Figure 3. The mean correlation for each sample with the normal samples (mean of 12 correlations for each tumor and 11 correlations for each normal) is shown. The 12 samples to the left of the vertical line are the normals. The 40 to the right are tumors. The horizontal line is drawn at the minimum mean correlation for the normals with normals.

(Supplementary Table 2, panel A). Of the 26, 17 regions were properly identified with methylation in PANC1 or both. Four regions identified as methylated by Sato and colleagues were not detected in our assay. There was disagreement in four regions. One gene RELN, which was reported as not methylated in either sample by Sato and colleagues, was found methylated in PANC1 cells. Interestingly, this gene is frequently methylated and silenced in pancreatic tumors (45), suggesting that our cell line may have genetically drifted over time apart from that used by Sato and colleagues. With our method we can obtain positional information for the region of the CpG island methylated and for all methylation events the region is very close to the TSS, the region critical for suppression of transcription. To determine the accuracy of methylation detection as well as the positional prediction we performed sodium bisulfite sequencing on the fragment, which was detected as methylated in the RELN CpG island in the PANC1 cell line. Interestingly, we found that the CpG island fragment at position chr7:103223731–103223823 is methylated (Supplementary Table 2, panel B) demonstrating that the method can accurately identify methylation and that positional information is also available. In addition we have determined that our line of PANC1 cells has deviated from the line used by SATO and colleagues.

The standard method to analyze tumor-methylation profiling is to utilize matched normal-tumor samples, and we have done this for 12 breast tumor and normal pairs. As with many tumor banks, ours contain many unmatched tumor samples. To determine if unmatched tumor-normal pairs could be analyzed first we compared our results obtained with matched samples to those obtained with unmatched samples as a set and measured the degree of common alterations. We developed statistical criteria for identifying CpG-islands most significantly altered between tumor and normal (see ‘Methods for details’ section). Our analysis identified considerable overlap (30%) of CpG-islands significantly altered (Supplementary Table 3) between a matched tumor-normal set (12 normals, 12 tumors) compared to an unmatched set (12 normals, 28 tumors). Since all tumor samples are different, similarity among a set could be a measure of tumor selection. We determined how different all 40 tumors were from the normal samples. We computed pair-wise correlations between each normal sample and the other normals and each tumor sample to each normal. From this data we then computed the mean correlation between each sample and the normal samples. The mean correlation from normals to normals is 0.93, from tumors to normals is .88 (P < 10E–017). These data (plotted in Figure 3) show that tumors are different from matched or unmatched normals. However, while some tumors are vastly different from normal several are more normal like in their methylation profile. In the future it will be interesting to have more detailed clinical information to determine if methylation profile can determine specific clinical parameters. Thus, we moved on to the analysis of a larger set of unmatched tumors and normals.

We then examined the set of 40 breast tumors, compared to 12 normal breast samples and 11 ovarian tumors compared to 7 normal ovarian samples (33). Using the statistical criteria developed (detailed in the ‘Methods’ section) we obtained a list of 916 significant alterations in breast cancer and 151 in ovarian cancer and have listed these by their genomic location (see Supplementary Table 4 for entire list and Table 2 for a summary of whether the alterations were found with more methylation or less methylation than normal, based on specific classes, non-promoter associated or promoter associated as well as non-island regions). In Table 1 we highlight genes selected based on functional information, many of which have previously been documented to alter methylation in cancer again demonstrating the ability of this methodology to detect CpG methylation. Genes identified hypermethylated in both ovarian and breast tumors include several HOX genes and protocadherins, known to be methylated in many tumor types (46–49). In addition to genes known to undergo methylation we have found new targets of methylation. For example, we detected for promoter methylation of a micro-RNA gene has-mir-9-3, occurring in more than half the breast tumors. This miRNA has been shown to be downregulated transcriptionally in thyroid cancers (50).

Another gene identified as methylated in the breast tumors, MTSS1 (metastasis suppressor 1) (Table 1) is known to be preferentially methylated in several cancers including breast cancer (51–53). To determine if our analytical methods identified this gene accurately, two primary tumors were identified with methylation from the dataset for further validation. Being that they were not cell lines we only had 25 ng of material that we wanted to check multiple times. Although bisulfite sequencing is generally used for validation we wished to use an alternative due to the small amount of genomic DNA remaining.
Others have utilized McrBC combine with PCR to study methylation (39, 54). Due to the constraints on us we chose to perform McrBC PCR (40) to validate the region of the island detected as methylated (Figure 4). The island was broken down into five fragments where fragment one overlaps the TSS up to fragment five that is the farthest away from the TSS. For tumors that were suspect to have methylation, fragment 1, which overlaps the gene TSS could not be amplified in the tumor samples (due to digestion by McrBC demonstrating methylation) as Table 1.

Table 1. Short list of genes selected from Supplementary Table 4 with altered CpG islands

| GeneName   | Name                      | Location                        | Importance                                         |
|------------|---------------------------|---------------------------------|----------------------------------------------------|
| Methylated |                            |                                 |                                                    |
| EPHA2      | Ephrin receptor A2         | chr1_16196139_16227870          | With E cadherin, mult roles in cancer              |
| HOXD11     | Homeodomain protein        | chr2_17679529_176795763         | Development and differentiation                     |
| HOXD9      | Homeodomain protein        | chr2_17680754_176807855         | Development and differentiation                     |
| PPM1G      | Protein phosphatase 1G     | chr2_2754151_27545066           | Cell cycle progression                              |
| RAB6B      | Ras oncogene family        | chr3_1350775_135098100          | G protein regulation of proliferation              |
| MFI2       | Melanoma-associated Ag 2   | chr3_19824566_198245644         | Melanoma tumor progression                         |
| IL17RB     | Interleukin 17 receptor B  | chr3_538551_53855185            | With HOXB13 progression in breast cancer           |
| HHP        | Hedgehog interacting protein| chr4_145923993_145924160       | Metastasis in pancre cancar                         |
| SFRP2      | Secreted frizzled related protein 2 | chr4_155067811_155068195 | Methylated is marker for colon cancer |
| CRMP1      | Collapsin response mediator prot 1 | chr4_601436_601469 | Wnt pathway, lung met suppression                   |
| PKD2       | Polycystic kidney disease 2| chr4_89285337_89285375          | Cell cycle                                         |
| PCDHGA10   | Protocadherin gamma, subfam A| chr5_14076806_140768556       | Cell adhesion                                      |
| HOXA2      | Homeodomain protein        | chr7_26919212_26919376          | Development and differentiation                     |
| HOXA3      | Homeodomain protein        | chr7_26942376_26942852         | Development and differentiation                     |
| EPDR1      | Ependymin related protein 1| chr7_3772893_37729281           | Ca²⁺ dependent cell adhesion                        |
| TAC1       | Tachykinin, precursor 1    | chr7_9300831_93008671           | Inflam prohormones; low act’y in brst cncr         |
| MTS1       | Metastasis suppressor 1    | chr8_125810238_125810819       | Metastasis suppressor                               |
| TNFRSF10D  | Tumor necrosis factor superfamily| chr8_23077244_23077520      | Progression neuroblastoma/breast cancer             |
| CUGBP1     | CUG triplet rpt, RNA bind prot | chr9_47531208_47531279   | Reg p21, cell cycle                                |
| NFYB       | Nuc. transcr. fctr Y beta  | chr12_103034912_103035336      | p53 cell cycle                                     |
| *PCDH8     | Protocadherin 8            | chr13_52320446_52320832        | Cell adhesion                                      |
| ONECUT1    | Onecut homeobox domain 1   | chr15_50874380_50874668        | Reg expression of FOXA2                             |
| CDH8       | Cadherin 8, type 2         | chr16_60627191_60627579        | Cell adhesion; freq deleted in brst cncr            |
| PPP1R14A   | Protein phosphatase 1 reg subunit 1A | chr19_4343912_43439444 | Reg act’y RAS and ERK in tumor lines |
| IL28A/B    | Interleukin 23 interferon like| chr19_4444759_44447674 | Inhibit tumor proliferation                         |
| FOXA2      | Forkhead box A2            | chr20_22514937_22515431        | Lung/prostate cancer                                |
| PLCG1      | Phospholipase C gamma 1    | chr20_3918472_39189934         | Implicated in cancer and metastatis                 |
| RTEL1      | Regulator telmerne elong.helicase | chr20_6175897_61759467  | Req for telomer elong.; chr breaks/loss            |
| PRR5       | Proline rich 5 (renal)     | chr22_43445548_43445907        | Downreg in breast cancer                           |
| SHOX       | Short stature homeobox     | chrX_551021_551221             | Reg of proliferation and viability                  |
| Demethylated |                        |                                 |                                                    |
| BRDT       | Bromo domain prot testis spec. | chr1_9126308_9126790             | Spermatogenesis                                    |
| RRM2       | Ribonucleotide reductase M2 | chr2_1021057_10212966           | Chemotherapy target                                |
| BCL11A     | B cell lymphoma protein 11A| chr2_6069409_60694350           | Cofactor w/ SIRT1 in transc’ip’n regulation         |
| DUB3       | Deubiquinating enzyme 3    | chr4_904795_9044135             | Proliferation                                      |
| RHOG       | Ras homolog gene family G  | chr11_3819507_3820119           | Apoptosis, migration                               |
| SULT1A1    | Sulforhodolate transferase family | chr16_28542367_28542407 | Response to therapy and prog. brst cancer |
| BECN1      | BCL2 interacting protein   | chr17_38228845_38228988         | Multiple roles in cancer                            |
| STRA13     | Stimulated by retinoic acid 13 | chr17_77754908_77757250   | Role in cell cycle and carcinogenesis              |
| MAPK1      | Map kinase 1/ERK           | chr22_20546877_20547317        | Proliferation                                      |

*Genes of possible functional interest were tabulated from the two categories based on TSS association. The gene abbreviation, full gene name, fragment location, and description of the gene are given.

Figure 4. McrBC PCR of two different fragments of the MTSS1 CpG island for tumors identified of having methylation of this island compared to matched normal samples. Fragment 1 encompasses the MspI fragment we have identified as being methylated and overlaps the gene TSS. Fragment 5, we do not detect methylation. Both Normal and Tumor were digested with McrBC or mock digested for both matched pairs.
Table 2. Summary of significant methylation changes listed in Supplementary Table 4 for breast cancer

| TSS associated (%) | Non-TSS associated (%) |
|--------------------|------------------------|
| CGI (801)          |                        |
| Methylated        | 166 (77.93)            |
| Demethylated      | 47 (22.07)             |
| Total             | 213                    |
| Non CGI (115)     |                        |
| Methylated        | 3 (33.33)              |
| Demethylated      | 6 (66.64)              |
| Total             | 9                      |
| Methylated        | 517 (87.92)            |
| Demethylated      | 71 (12.07)             |
| Total             | 588                    |
| Methylated        | 23 (21.70)             |
| Demethylated      | 83 (78.30)             |
| Total             | 106                    |

*aAll methylation and demethylation events from Supplemental Table 4 were broken down into categories of associated to a gene (TSS associated) or not (Non-TSS associated), and methylated or demethylated within each of these groups. Finally the probes are divided based on inclusiveness to a CpG island or the probes that are non-CGI probes. The total number is given for breast cancer comparison as well as the conversion to percentages in parentheses.

DISCUSSION

We have designed a methylation array and developed statistical methods to detect CpG methylation. This methodology was performed on cell lines and measurements validated with more standard methods. Comparing the analysis of two cell lines by our methodology allowed us to test the accuracy by bisulfite sequencing fragments with differential methylation between the two cell lines. We found no errors except for one fragment that was methylated but was not detected. This could have been a failure of the McrBC or the array detection. We suspect the oligonucleotide probe since as in all hybridization-based method, there are bound to be probes that do not report well. In comparison of our method with another array-based methods for the analysis of the same samples, we found good correspondence between the two methods. One gene we found particularly interesting, RELN, is frequently silenced in pancreatic cancer. Sato and colleagues demonstrate that it is not methylated in this particular pancreatic cancer cell line but our measurements suggest that it is methylated. Judging from its frequency of silencing and our success in validation of our measurements it is likely that our version of the cell line has genetically, or in this case, epigenetically drifted from that used by Sato and colleagues. To determine if this was the case we validated our findings by bisulfite sequencing and determined that our version of the cell line had deviated and the array was correct in its measurement.

In our analysis of tumors versus normal, as expected, the tumors had more variation than the normals. However, some tumors were remarkably similar while others very different from their matched normal. More importantly, the unmatched tumors were for the most part similar in variation to normal as the matched tumors. Three breast tumors out of 40 and 2 ovarian tumors out of 11 were extremely different from the normals, which could be interesting in reference to clinical parameters or genome structure and we are investigating this further with sample sets of a larger size. We then developed statistical methods that could be used to identify those CpG islands that differ in their methylation status in the tumors as compared to the normals.

We have identified a number of CpG islands, both associated with gene TSSs or islands far from the TSS for any genes, which have altered methylation from both breast and ovarian tumors as compared to normal. However, we did not identify well-known tumor suppressors in the primary tumor dataset such as \( p16 \). The lack of known tumor suppressors could be a fault in our analysis or our methods. However, the frequency of methylation for many classically known tumor suppressors varies widely, some being as low as 15% (55–58). Using \( p16 \) as an example, analysis of the tumor samples with matched normals did not uncover tumor suppressors such as \( p16 \) and since we demonstrate the ability to detect \( p16 \) methylation in the cell line HuH7 (43) with known methylation it is likely that none of the tumors had methylation of \( p16 \). Therefore, although improvements are always possible, we feel that our technical and analytical methods are sound. Unfortunately, the tumor suppressor Rassf1a that is a common target of methylation in cancer is not measurable with the current array. The next generation array will include better design of CpG islands such as those proximal to the Rassf1a.

One disadvantage of our method of analysis is that those genes whose CGIs are found with altered methylation in few samples may not be identified. The MiR-196 loci on chromosome 17 is methylated in several of the breast cancers in our study as compared to matched normals but overall is not significant in the larger set. It has been previously shown that the miR-196 directs the cleavage of HoxB8 mRNA (59), which appears to function in myeloid differentiation (60,61), however it is possible that it plays a role in the deregulation of breast cells in becoming cancer. Presently we are further developing our statistical methods to improve our level of detection.

Of the islands associated with gene TSSs identified as methylated there are a number that have been found altered and/or have been shown by other to decrease in expression in cancer, such as \( MTSS1 \) (51–53). We found this island methylated in a number of the primary breast tumors and verified by McrBC PCR (54) that it was methylated in two of these (one such sample shown in Figure 4). Tumor suppressors that are methylated are often found in regions of loss of heterozygosity (LOH). It will be interesting to determine which of the genes found methylated are in regions of LOH. It is interesting that \( MTSS1 \) is found on the q arm of chromosome 8, which is
amplified very frequently in breast cancer and ovarian tumors. It is possible that MTSS1 loss is important to the tumor growth as suggested by its role in cytoskeletal rearrangement (62) and its correlation with the disease state (51), so that in order to ensure lack of transcription within a region of genomic amplification the gene is silenced by methylation. It will be interesting to associate CGH data with methylation data and incorporate expression analysis to identify genes that are methylated and suppressed and determine if they are amplified or deleted genomically.

Of the genes identified, those that are functionally interesting should have their methylation validated by other means such as bisulfite sequencing or McrBC PCR. Those that pass can be functionally validated as candidates with possible tumor-suppressive activity. In conclusion, we have developed a powerful method to profile genome-wide DNA methylation. We have demonstrated that there is very low system noise from either the representational process or the labeling and hybridization. We then legitimized the method’s ability to detect methylation by bisulfite sequence validating over 15 fragments. We went on to analyze a number of samples that have been analyzed by others either by bisulfite sequencing or by other genome-wide approaches for methylation detection (43,45). In the case of Maeta et al., we have validated specific methylation events and in the case of Sato et al. we have reproduced the majority of their findings using our methodology. We then used this method to develop methods for the analysis of tumors with unmatched normals, which will be of interest to the greater community since many tumor banks do not have matched normals. We plan on using this methodology to identify methylation events that correlate to clinical parameters to determine if tumor sub-classification can be achieved, markers from this type of analysis being very valuable. In addition, this methodology will have utility in the study of other pathologies, such as imprinting, development, or tissue specificity, which all are affected by epigenetic modifications.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS
We thank Scott Powers, Scott Lowe, Michael Wigler and Michael Zhang for critical comments on the manuscript. We also thank Christopher Johns for assistance in design of the arrays. Some tumor samples were supplied by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute. Other investigators may have received samples from these same tissues.

FUNDING
National Institutes of Health and National Cancer Institute [K01CA93634-01 to R.L.]; Department of Defense [W81XWH-05-1-0068 to R.L.] as well as by grants awarded to Michael Wigler from the Simons Foundation and the Breast Cancer Research Foundation. Funding for open access charge: awarded to to RL and Michael Wigler from Philips Research North America.

Conflict of interest statement. None declared.

REFERENCES
1. Gardiner-Garden,M. and Frommer,M. (1987) CpG islands in vertebrate genomes. J. Mol. Biol., 196, 261–282.
2. Takai,D. and Jones,P.A. (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA, 99, 3740–3745.
3. Herman,J.G. and Baylin,S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042–2054.
4. Baylin,S.B., Herman,J.G., Graff,J.R., Vertino,P.M. and Issa,J.P. (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72, 141–196.
5. Bird,A.P. (1996) The relationship of DNA methylation to cancer. Cancer Surv., 28, 87–101.
6. Lavie,L., Kitova,M., Maldener,E., Meece,E. and Mayer,J. (2005) CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J. Virol., 79, 876–883.
7. Roman-Gomez,J., Jimenez-Velasco,A., Agirre,X., Cervantes,F., Sanchez,J., Garate,L., Barrios,M., Castillejo,J.A., Navarro,G., Colomer,D. et al. (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene, 24, 7213–7223.
8. Cho,N.Y., Kim,B.H., Choi,M., Yoo,E.J., Moon,K.C., Cho,Y.M., Kim,D. and Kang,G.H. (2007) Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J. Pathol., 211, 269–277.
9. Smith,I.M., Mydlarz,W.K., Mithani,S.K. and Califano,J.A. (2007) DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int. J. Cancer, 121, 1724–1728.
10. Ehrlich,M. (2002) DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J. Nutr., 132, 2424S–2429S.
11. Bird,A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev., 16, 6–21.
12. Merlo,A., Herman,J.G., Mao,L., Lee,D.J., Gabrielson,E., Burger,P.C., Baylin,S.B. and Sidransky,D. (1995) 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1, 686–692.
13. Dammann,R., Li,C., Yoon,J.H., Chin,P.L., Bates,S. and Pfeifer,G.P. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25, 315–319.
14. Rice,J.C., Massey-Brown,K.S. and Futscher,B.W. (1998) Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA levels in sporadic breast cancer cells. Oncogene, 17, 1807–1812.
15. Shames,D.S., Minna,J.D. and Gazdar,A.F. (2007) DNA methylation in health, disease, and cancer. Curr. Mol. Med., 7, 85–102.
16. Estecio,M.R., Yan,P.S., Ibrahim,A.E., Tellez,C.S., Shen,L., Huang,T.H. and Issa,J.P. (2007) High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res., 17, 1529–1536.
17. Bibikova,M., Lin,Z., Zhou,L., Chudinz,E., Garcia,E.W., Wu,B., Doucet,D., Thomas,N.J., Wang,Y., Vollmer,E. et al. (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res., 16, 383–393.
18. Weber,M., Davies,J.J., Wittig,D., Oakeley,E.J., Haase,M., Lam,W.L. and Schubeler,D. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA
56. Brenner, A.J., Paladugu, A., Wang, H., Olopade, O.I., Dreyling, M.H. and Aldaz, C.M. (1996) Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin. Cancer Res., 2, 1993–1998.

57. Dammann, R., Yang, G. and Pfeifer, G.P. (2001) Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61, 3105–3109.

58. Silva, J., Silva, J.M., Dominguez, G., Garcia, J.M., Cantos, B., Rodriguez, R., Larrondo, F.J., Provencio, M., Espana, P. and Bonilla, F. (2003) Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J. Pathol., 199, 289–297.

59. Yekta, S., Shih, I.H. and Bartel, D.P. (2004) MicroRNA-directed cleavage of HOXB8 mRNA. Science, 304, 594–596.

60. Fujino, T., Yamazaki, Y., Largaespada, D.A., Jenkins, N.A., Copeland, N.G., Hirokawa, K. and Nakamura, T. (2001) Inhibition of myeloid differentiation by Hoxa9, Hoxb8, and Meis homeobox genes. Exp. Hematol., 29, 856–863.

61. Knoepfler, P.S., Sykes, D.B., Pasillas, M. and Kamps, M.P. (2001) HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation. Oncogene, 20, 5440–5448.

62. Mattila, P.K., Salminen, M., Yamashiro, T. and Lappalainen, P. (2003) Mouse MIM, a tissue-specific regulator of cytoskeletal dynamics, interacts with ATP-actin monomers through its C-terminal WH2 domain. J. Biol. Chem., 278, 8452–8459.